CW Advisors LLC Makes New $416,000 Investment in Biogen Inc. $BIIB

Key Points

• CW Advisors LLC recently acquired a new stake in Biogen Inc., purchasing 3,033 shares valued at approximately $416,000, signaling growing institutional interest in the biotechnology company.
• Biogen reported $5.47 EPS for its quarterly earnings, outperforming the consensus estimate of $3.93 and reflecting a revenue increase of 7.3% year-over-year.
• Analysts have mixed opinions on Biogen, with recent ratings showing a consensus "Hold" and price targets ranging from $115.00 to $300.00, indicating varying outlooks on the stock's future performance.

CW Advisors LLC purchased a new stake in Biogen Inc. (NASDAQ:BIIB - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 3,033 shares of the biotechnology company's stock, valued at approximately $416,000.

Several other institutional investors have also recently added to or reduced their stakes in BIIB. Integrated Wealth Concepts LLC lifted its stake in Biogen by 185.1% in the fourth quarter. Integrated Wealth Concepts LLC now owns 4,479 shares of the biotechnology company's stock valued at $685,000 after buying an additional 2,908 shares during the period. Coldstream Capital Management Inc. boosted its holdings in Biogen by 16.6% in the fourth quarter. Coldstream Capital Management Inc. now owns 2,795 shares of the biotechnology company's stock worth $427,000 after acquiring an additional 398 shares in the last quarter. Beacon Pointe Advisors LLC boosted its holdings in Biogen by 10.7% in the fourth quarter. Beacon Pointe Advisors LLC now owns 1,537 shares of the biotechnology company's stock worth $235,000 after acquiring an additional 149 shares in the last quarter. Northern Trust Corp boosted its holdings in Biogen by 14.6% in the fourth quarter. Northern Trust Corp now owns 1,550,130 shares of the biotechnology company's stock worth $237,046,000 after acquiring an additional 196,995 shares in the last quarter. Finally, Lido Advisors LLC boosted its holdings in Biogen by 2,364.3% in the fourth quarter. Lido Advisors LLC now owns 41,598 shares of the biotechnology company's stock worth $6,361,000 after acquiring an additional 39,910 shares in the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

Biogen Stock Performance

Shares of BIIB traded down $0.43 on Monday, reaching $132.22. 1,081,750 shares of the company's stock traded hands, compared to its average volume of 1,387,363. The company has a current ratio of 2.50, a quick ratio of 1.79 and a debt-to-equity ratio of 0.36. The stock has a market cap of $19.39 billion, a PE ratio of 12.64, a PEG ratio of 1.04 and a beta of 0.11. The stock's 50 day simple moving average is $131.40 and its two-hundred day simple moving average is $130.53. Biogen Inc. has a 52-week low of $110.04 and a 52-week high of $206.70.

Biogen (NASDAQ:BIIB - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The biotechnology company reported $5.47 EPS for the quarter, beating analysts' consensus estimates of $3.93 by $1.54. The company had revenue of $2.65 billion during the quarter, compared to the consensus estimate of $2.32 billion. Biogen had a return on equity of 13.85% and a net margin of 15.31%.Biogen's revenue was up 7.3% on a year-over-year basis. During the same period last year, the business posted $5.28 earnings per share. Biogen has set its FY 2025 guidance at 15.500-16.000 EPS. On average, analysts forecast that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Insider Activity at Biogen

In related news, insider Rachid Izzar sold 2,223 shares of the stock in a transaction that occurred on Tuesday, July 8th. The stock was sold at an average price of $135.00, for a total transaction of $300,105.00. Following the completion of the sale, the insider directly owned 6,330 shares of the company's stock, valued at approximately $854,550. This trade represents a 25.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.18% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on BIIB shares. HC Wainwright increased their price target on Biogen from $187.00 to $194.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Truist Financial assumed coverage on Biogen in a report on Monday, July 21st. They issued a "hold" rating and a $142.00 price target on the stock. Citigroup increased their price objective on Biogen from $125.00 to $135.00 and gave the stock a "neutral" rating in a research note on Friday, August 1st. Royal Bank Of Canada increased their price objective on Biogen from $208.00 to $219.00 and gave the stock an "outperform" rating in a research note on Friday, August 1st. Finally, Morgan Stanley lowered their price objective on Biogen from $146.00 to $144.00 and set an "equal weight" rating for the company in a research note on Friday, August 1st. Eleven investment analysts have rated the stock with a Buy rating and twenty-one have assigned a Hold rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $185.74.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.